NDAINJECTIONINJECTABLEPriority Review
Approved
May 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZINECARD (dexrazoxane hydrochloride) is a small-molecule cardioprotective agent administered by injection to reduce cardiotoxicity associated with doxorubicin chemotherapy in patients with metastatic breast cancer. It works as a topoisomerase II inhibitor and iron chelator that protects cardiac tissue from anthracycline-induced damage.
LOE Approaching
As LOE approaches, the brand team is likely scaling down, with focus shifting to managed decline and cost optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZINECARD offers limited career growth given zero linked job openings and LOE-approaching status. This role suits professionals comfortable with defensive brand management, account retention, and managed decline strategies rather than innovation-focused career trajectories.
Brand ManagerField Sales Representative
Worked on ZINECARD at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.